DailyDoctor Archive Specialties Get app
All infectious diseases briefings

The edition · Infectious Diseases

Adding cefixime to azithromycin did not reduce typhoid treatment failure

A South Asian trial of 1831 patients backs azithromycin alone. Also: a mortality signal for cefepime, carbapenem resistance in Asian hospitals, nirmatrelvir for long COVID, and a Baxter vancomycin recall.

The edition in brief

ACT-South Asia randomised 1847 adults and children with suspected or confirmed uncomplicated typhoid in Nepal, Bangladesh and Pakistan to azithromycin plus cefixime or azithromycin plus placebo for 7 days. Treatment failure was 5.1% in both groups, supporting azithromycin alone. A Bayesian meta-analysis of 110 randomised trials (22,608 patients) found a 94.4% probability that cefepime carries higher mortality than other beta-lactams (OR 1.10), rising to 98.6% in peer-reviewed trials (OR 1.17). ACORN-HAI followed 9496 patients with ventilator-associated pneumonia or hospital bloodstream infection in 41 Asian hospitals: 73.7% of infections involved resistant bacteria, and 28-day mortality was 51.3% with carbapenem-resistant Acinetobacter and 48.4% with carbapenem-resistant Enterobacterales. RECOVER-VITAL found no benefit from 15 or 25 days of nirmatrelvir-ritonavir across cognitive, autonomic or exercise phenotypes of long COVID. The FDA lists a Class II recall of Baxter's premixed vancomycin in dextrose for manufacturing-practice deviations. Today's pearl: write down the planned stop date whenever an antibiotic is started.

In this edition
01
Clinical update

Cefepime linked to higher mortality than other beta-lactams across 110 trials

Where an equally suitable beta-lactam is available, prefer it to cefepime, and dose cefepime carefully for renal function when you do use it.

2 min · JAMA network openRead →
Primary outcome
All-cause mortality, about 30 days
Effect
6.6% vs 6.2%, OR 1.10 (95% CrI 0.98–1.24), 94.4% probability of harm; peer-reviewed trials OR 1.17 (1.02–1.34)
02Clinical update

Carbapenem-resistant infections kill about half of patients in Asian hospitals

Treat prevention of ventilator and line infections as mortality control, and involve microbiology early for every carbapenem-resistant isolate.

1 min · The Lancet. Infectious diseasesRead →
03Research

Nirmatrelvir-ritonavir did not help long COVID in any symptom group

Do not use nirmatrelvir-ritonavir for long COVID; manage symptoms directly.

1 min · The Lancet. Infectious diseasesRead →
04Regulatory

FDA Class II recall: Baxter premixed vancomycin in dextrose

If your hospital stocks Baxter premixed vancomycin bags, check lots and switch to vial-prepared infusions.

1 minRead →
05Pearl

Write the stop date when you start the antibiotic

Every time you start an antibiotic, write the indication and the planned stop date on the chart.

1 minRead →
06
Practice changer

Azithromycin alone is enough for uncomplicated typhoid; adding cefixime did not help

Treat uncomplicated typhoid with azithromycin alone for 7 days; adding cefixime did not reduce failure.

2 min · The Lancet. Infectious diseasesRead →
Primary outcome
Composite treatment failure within 28 days
Effect
5.1% vs 5.1%, risk difference 0.00 points (95% CI −2.08 to 2.08); culture-confirmed 11.2% vs 16.0%

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free